Intra-Cellular Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 610
- Market Cap
- $7.8B
- Introduction
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate,...
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT04959032
- Locations
- 🇷🇸
Clinical Site, Novi Kneževac, Serbia
🇷🇸Clinical site, Belgrade, Serbia
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04934124
- Locations
- 🇺🇸
Clinical Site, Eatontown, New Jersey, United States
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04779177
- Locations
- 🇺🇸
Clinical Site, Decatur, Georgia, United States
Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT04709224
- Locations
- 🇺🇸
Clinical Site, Marlton, New Jersey, United States
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 488
- Registration Number
- NCT04285515
- Locations
- 🇺🇦
Clinical Site, Vinnytsia, Ukraine
🇺🇦Clinical site, Odesa, Ukraine
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03489772
- Locations
- 🇺🇸
Laureate Institute for Brain Research, Inc., Tulsa, Oklahoma, United States
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03387215
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03257046
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Duke Early Phase Research Unit, Durham, North Carolina, United States
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 381
- Registration Number
- NCT03249376
- Locations
- 🇺🇦
Clinical Site, Vinnytsia, Ukraine
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02817906